DC Chemicals · Product datasheet

TTC-352 — Datasheet

CAT. NO. DC70851

Product page and current package options

ParameterValue
Chemical NameUnii-65ilh3Y0MI
CAS No.1607819-68-0
Synonyms65ILH3Y0MI;3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol;3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol;3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol;BDBM50145856;J3.603.123I;2-(4-Hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol;3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol;3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol;3-(4-fluoro;Unii-65ilh3Y0MI
FormulaC20H13FO3S
M.Wt352.378827810287
SMILESS1C(=C(C2C=CC(=CC=2)F)C2C=CC(=CC1=2)O)OC1C=CC(=CC=1)O
Purity>97%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

TTC-352 is a synthetic selective estrogen mimic acts as estrogen receptor (ER) partial agonist for the treatment of endocrine-resistant breast cancer.TTC-352 yields an H-bond with Glu353, allows Asp351-to-helix 12 (H12) interaction, sealing ERα's ligand-binding domain, recruiting E2-enriched coactivators, and triggering rapid ERα-induced unfolded protein response (UPR) and apoptosis.TTC-352 is a less potent full estrogen agonist compared to E2, allowing H12 to seal the LBD, which recruits many E2-enriched coactivators, and induces rapid ERα-mediated UPR and apoptosis.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

1. Balkees Abderrahman, et al. Mol Cancer Ther. 2021 Jan;20(1):11-25.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation